CDMO Bespak and the fluoroproduct specialist faction of Orbia Advance Corporation, Fluor & Energy Materials, have entered into a collaboration to create climate-friendly inhalers.
The CDMO will utilise Orbia Fluor & Energy Materials' low-GWP propellant Zephex 152a to achieve this.
To improve the sustainability credentials of its pMDI formulations, Bespak has been incorporating low GWP propellants into a range of its inhaled drug products.
According to Bespak, this was an achievement enabled by its range of valves and its network of expert partners.
Following investments into this area, Bespak can now provide development services up to market approval for all pMDI formulations and propellants.
Most recently, Bespak announced the availability of its clinical supply services utilising HFA-152a as a result of its partnership with H&T Presspart, and its investment in a new high-speed commercial-scale filling line capable of manufacturing with HFA-152a, both at the company’s Holmes Chapel site.
By combining Orbia Fluor & Energy Materials' Zephex 152a and its own GLP and clinical-scale GMP capacity with Bespak's capabilities, the companies plan to reformulate and re-commercialise pMDI products with a more favourable sustainability profile globally.
Bespak's King's Lynn, UK team will also provide a range of vales and actuators to ensure the optimal performance of next-gen propellants, allowing for the more efficient reformulation and development of pMDI products.
CEO of Bespak, Chris Hirst, commented: “We are committed to leading the transition to low GWP propellants in pMDIs, and in collaboration with Orbia Fluor & Energy Materials, we will enable customers to progress their inhaler portfolios utilising Zephex 152a."
"Our goal is to convert as many formulations as possible to maintain patient access to pMDIs as global regulation evolves, and we look forward to working with Orbia Fluor & Energy Materials to provide customers with a pathway to commercialisation at our Holmes Chapel site.”
General Manager of Orbia Fluor & Energy Materials Pharma Business Unit, Markus Laubscher, said: “This is another step forward in bringing pMDIs using our low GWP medical propellant Zephex 152a to the market."
"We are excited to extend our industry collaborations to Bespak who bring the needed capabilities to the table, from their expertise in valves and actuators, to their demonstrated commitment to clinical and commercial-scale product manufacturing.”
